|1.||Moody, Christopher J: 6 articles (07/2014 - 05/2002)|
|2.||Ross, David: 5 articles (07/2014 - 05/2007)|
|3.||Siegel, David: 5 articles (07/2014 - 05/2007)|
|4.||Yan, Chao: 3 articles (07/2014 - 07/2009)|
|5.||Chilloux, Aurélie: 3 articles (07/2009 - 05/2007)|
|6.||Reigan, Philip: 3 articles (07/2009 - 05/2007)|
|7.||Colucci, Marie A: 3 articles (07/2009 - 05/2007)|
|8.||Inman, Martyn: 1 article (07/2014)|
|9.||Visconti, Andrea: 1 article (07/2014)|
|10.||Totzke, Frank: 1 article (07/2012)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
07/01/2009 - "The objective of this study was to identify indolequinones with improved potency against pancreatic cancer and to define their mechanisms of action. "
07/21/2014 - "An important determinant of the growth inhibitory activity of indolequinones against pancreatic cancer cells is substitution on the 2-position with 2-unsubstituted derivatives being markedly more potent. "
07/21/2014 - "Antitumour indolequinones: synthesis and activity against human pancreatic cancer cells."
07/01/2009 - "Pancreatic cancer cell lines PANC-1, MIA PaCa-2, and BxPC-3 were used in in vitro assays [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) and clonogenic assays]; indolequinones displayed potent cytotoxicity against all three cell lines, and two specific classes of indolequinone were particularly potent agents. "
11/15/2007 - "However, the data demonstrate that NQO1 inhibition does not correlate with growth inhibitory activity, at least in the MIA PaCa-2 cell line, suggesting that targets in addition to NQO1 need to be considered to explain the potent growth inhibitory activity of this series of indolequinones in human pancreatic cancer cells."
11/15/2007 - "The ability of these indolequinones to function as mechanism-based inhibitors of purified recombinant human NQO1 was evaluated, as was their ability to inhibit both NQO1 and cell growth in human pancreatic MIA PaCa-2 tumor cells. "
07/01/2009 - "In vivo efficacy of the indolequinones was also tested in the MIA PaCa-2 pancreatic tumor xenograft in nude mice, and lead indolequinones demonstrated high efficacy and low toxicity. "
07/01/2009 - "Selected indolequinones were also screened against the NCI-60 cell line panel and were found to be particularly effective against colon, renal, and melanoma cancer cells. "
07/20/2012 - "Novel indeno[1,2-b]indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines."
02/10/2000 - "Design of cancer-specific antitumor agents based on aziridinylcyclopent[b]indoloquinones."
|3.||Melanoma (Melanoma, Malignant)
05/01/2002 - "In conclusion, it is possible to modify rates of reductive elimination from indolequinones to control the release of drugs over a range of tumour hypoxia."
05/01/2002 - "Rates of reductive release of the fluorophore from the non-fluorescent parent indolequinones (R=H, Me, thienyl) were similar under anoxia ( approximately 1.7 nmol coumarinmin(-1)mg protein(-1)) reflecting the similarity in one-electron reduction potential. "
09/01/1998 - "Targeting hypoxia with a new generation of indolequinones."
|5.||Lung Neoplasms (Lung Cancer)
03/03/1998 - "A series of indolequinones bearing various functional groups has been synthesized, and the effects of substituents on the metabolism of the quinones by recombinant human NAD(P)H:quinone oxidoreductase (NQO1), and on the toxicity toward nonsmall cell lung cancer cells with either high NQO1 activity (H460) or with no detectable activity (H596) were studied."
|2.||Antineoplastic Agents (Antineoplastics)
|3.||Casein Kinase II (Casein Kinase 2)
|5.||Protein Kinases (Protein Kinase)
|1.||Heterologous Transplantation (Xenotransplantation)